Suzhou Ribo Life Science (HKEX: 6938) wants to start testing an experimental obesity drug in people. The siRNA developer and its Swedish subsidiary, Ribocure Pharmaceuticals AB, said on October 7 that they have submitted a Phase 1 clinical trial application (CTA) in the European Union for RBD3133, a drug that targets a gene called INHBE.

That is a filing. Nothing has been approved, and no one has been dosed.

Still, it puts Ribo, which listed in Hong Kong in January, into one of the most closely watched new target races in obesity. It is also a race where a rival’s early human data has already shown how quickly investor enthusiasm can turn.

What Ribo Filed

RBD3133 is a small interfering RNA, or siRNA. Drugs in this class silence a specific gene by destroying its messenger RNA before the cell can turn it into protein. The target here, INHBE, is a gene active mainly in the liver. It makes a hormone called activin E, which appears to influence where the body stores fat.

The planned study is randomized and placebo-controlled. It will measure safety, tolerability, pharmacokinetics (how the body absorbs and clears the drug) and pharmacodynamics (what the drug does to its target) in people with overweight or obesity, with RBD3133 given as an injection under the skin.

Ribo describes overweight and obesity as the drug’s intended future indications. That wording is accurate and worth keeping in mind. A first-in-human safety study is not built to prove weight loss, and Ribo does not claim this one will.

What the Release Leaves Out

A lot. Ribo did not say how many people the trial will enroll, which EU countries or sites are involved, what doses will be tested, or when it expects to dose the first participant. It shared no preclinical data on RBD3133 at all. No animal weight-loss figures. Nothing on how often the drug might be given.

Under the EU’s Clinical Trials Regulation, sponsors file a single application through the Clinical Trials Information System, and the member states where the trial will run assess it together. The trial cannot start until they authorize it. Ribo gave no timeline for that decision.

The release also calls RBD3133 poised to become a cornerstone drug for weight-related cardiometabolic disease. That is the company’s characterization. The drug has not yet been given to a human.

Why Drugmakers Like INHBE

The case for INHBE starts with human genetics, not mice. In 2022, two separate studies in Nature Communications, one led by Alnylam Pharmaceuticals researchers and one by the Regeneron Genetics Center, found that people born with naturally disabled copies of the gene tend to carry less abdominal fat relative to their overall size. The Regeneron-led study also tied those variants to protection from type 2 diabetes.

The Alnylam-led analysis drew on exome sequences from about 363,000 people. Carriers are rare, roughly one in 587 in that dataset, and Alnylam reported no signs of harm linked to the variants.

The pitch writes itself. A drug that copies that profile might trim fat, especially the visceral fat packed around organs, without working through appetite the way GLP-1 drugs such as semaglutide and tirzepatide do. And because siRNAs can last for months, developers hope for infrequent dosing. Ribo’s release echoes the genetic argument but does not cite a specific study.

Its figure of more than one billion people living with obesity worldwide lines up with a 2024 Lancet analysis publicized by the World Health Organization.

A Crowded Race, and a Warning Shot

Ribo is starting well behind.

Wave Life Sciences (Nasdaq: WVE) has the most human data with WVE-007, its own INHBE siRNA. In March 2026, Wave reported six-month results from a single 240 mg dose showing reductions in fat, particularly visceral fat, with lean mass preserved. Body weight, though, fell only about 1%, according to Clinical Trials Arena. Wave’s stock dropped nearly 50% in a day. The company has since started dosing in a multidose Phase 2a portion of its INLIGHT trial.

Arrowhead Pharmaceuticals (Nasdaq: ARWR) is testing ARO-INHBE in a Phase 1/2a study, alone and with tirzepatide. In four patients with obesity and type 2 diabetes, two doses of ARO-INHBE plus tirzepatide produced 9.4% weight loss at week 16, versus 4.8% for placebo plus tirzepatide, Fierce Biotech reported. Four patients is a very small group.

Alnylam (Nasdaq: ALNY) lists an INHBE program in its obesity pipeline. Closer to home, China Medical System (HKEX: 867) won Chinese clearance in March 2026 to begin trials of its own INHBE siRNA, CMS-D008.

None of these drugs is approved. None has been tested head-to-head against RBD3133, and the trials differ in design and patient population, so any comparison across programs is suggestive at best.

Who Is Ribo?

The release lists Ribo’s ticker but offers investors little else. Founded in 2007, Ribo listed on the Main Board of the Hong Kong Stock Exchange on January 9, 2026, under Chapter 18A, the exchange’s route for biotech companies that are not yet profitable. The IPO raised about HK$1.83 billion, or roughly US$235 million, according to law firms that advised on the deal.

Its core product is RBD4059, an siRNA aimed at Factor XI for thrombotic disease. At the time of listing, Ribo reported seven in-house drug candidates in clinical trials across cardiovascular, metabolic, kidney and liver disease. RBD3133 is its first obesity candidate, per the release.

What to Watch

First, whether EU regulators authorize the trial, and when dosing begins. Second, whether Ribo publishes preclinical data that would let outsiders size up RBD3133 against rivals.

The bigger question belongs to the whole class. INHBE drugs still have to show they can move the scale, not only reshape body composition. The next readouts from Wave and Arrowhead will likely set expectations for every program behind them, Ribo’s included.

This article covers a regulatory filing for an investigational drug and is not medical or investment advice.

Sources

• Suzhou Ribo Life Science: Ribo Submits European Clinical Trial Application for Phase I Study of INHBE-Targeting siRNA RBD3133, PRNewswire, October 7, 2026. Primary source release.
• Kirkland & Ellis: Kirkland Advises Ribo Life on its Hong Kong IPO, cited for Ribo’s founding year, IPO proceeds, core product RBD4059, and clinical pipeline size, none of which appeared in the release.
• O’Melveny: O’Melveny Advises on Ribo Life Science’s US$235 Million Hong Kong IPO, cited for the January 9, 2026 listing date, Chapter 18A listing route, and US dollar IPO value.
• Deaton et al., Rare loss of function variants in the hepatokine gene INHBE protect from abdominal obesity (Nature Communications, 2022), cited for the human genetic evidence behind INHBE as a target and the study size.
• Akbari et al., Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes (Nature Communications, 2022), cited for the Regeneron-led genetic study linking INHBE variants to type 2 diabetes protection.
• Alnylam Pharmaceuticals: Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity, cited for carrier frequency and the absence of adverse associations.
• Clinical Trials Arena: Wave’s stock crashes 50% on Phase I obesity data, cited for WVE-007 six-month results and Wave’s share price reaction.
• Wave Life Sciences: Second Quarter 2026 Financial Results (SEC Form 8-K), cited for the start of the multidose Phase 2a portion of the INLIGHT trial.
• Fierce Biotech: Arrowhead takes aim at obesity market with early data on dual gene silencing assets, cited for ARO-INHBE plus tirzepatide weight-loss data and patient count.
• China Medical System: Self-Developed INHBE-Targeting siRNA Drug Received IND Approval for Overweight/Obesity, cited for the CMS-D008 trial clearance in China.
• Alnylam puts siRNA with undisclosed target into Phase I for obesity management (AllSci), cited for Alnylam’s INHBE obesity program.
• European Medicines Agency: Clinical Trials Regulation, cited for how EU clinical trial applications are submitted and authorized.
• World Health Organization: One in eight people are now living with obesity, cited to check the release’s global obesity figure against the 2024 Lancet analysis.

Editorial Disclosure

This article is based on a press release issued by Suzhou Ribo Life Science Co., Ltd. on October 7, 2026 regarding the submission of a European Union Phase 1 Clinical Trial Application for RBD3133. Securities and corporate structures discussed: Suzhou Ribo Life Science Co., Ltd. (Hong Kong Stock Exchange: 6938, including its subsidiary Ribocure Pharmaceuticals AB), Wave Life Sciences Ltd. (Nasdaq: WVE), Arrowhead Pharmaceuticals, Inc. (Nasdaq: ARWR), Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), and China Medical System Holdings Limited (Hong Kong Stock Exchange: 867). Details on Ribo’s listing and pipeline, the human genetic evidence behind INHBE, and competing INHBE programs were drawn from the independent sources cited above, since the original release did not address them. BioTech Stocks Daily has not received, nor will it accept, any compensation, direct or indirect, from Suzhou Ribo Life Science, Ribocure Pharmaceuticals, or any other corporate or third-party sponsor for the preparation or publication of this coverage. No staff member, principal, or affiliate of BioTech Stocks Daily holds a position, option, or financial interest in any of the securities mentioned as of the date of publication. Statements regarding regulatory authorization of the RBD3133 trial, the timing of first dosing, future clinical development, intended therapeutic indications, and potential competition are forward-looking statements. They involve substantial risks, regulatory uncertainties, and scientific variables; actual clinical outcomes, development timelines, and regulatory decisions may differ materially. Clinical-stage biotechnology investments carry an extreme degree of financial risk. Drug development is subject to high rates of clinical failure, regulatory rejection, and market competition, which can result in the total loss of invested capital. This article is published strictly for independent news reporting, market context, and educational purposes only. It does not constitute an investment recommendation, endorsement, or professional financial, legal, or tax advice. Furthermore, this content is not medical advice; patients and healthcare providers should consult appropriate clinical professionals for medical guidance.

For full details regarding our editorial independence, publishing policies, and comprehensive risk disclaimers, see our full DISCLAIMER.